What did @arijai_texas actually say?
The creator argues that "you don't have to be older" to experience hormonal decline, pointing to perimenopause symptoms starting "as early as our 30s." She lists brain fog, weight gain difficulty, low libido, hot flashes, anxiety, and sleep disorders as hormone-related. Her pitch: bioidentical hormone replacement therapy (BHRT) can address these symptoms while also accounting for thyroid and vitamin D levels, which she calls "team players" in the perimenopause picture.
One notable slip worth flagging: she says the clinic looks "only just at your sex hormones" before correcting herself to say they look beyond them. The intent seems clear, but the phrasing is worth noting for anyone parsing the script carefully.
Does the science back this up?
Mostly, yes, though with some important asterisks. The claim that perimenopause can begin in the 30s is supported by research, and the symptom list is largely accurate. The BHRT framing is where things get more contested.
The average age of perimenopause onset is the mid-to-late 40s, but research published by the Study of Women's Health Across the Nation (SWAN) has documented hormonal fluctuations, irregular cycles, and vasomotor symptoms in women as young as their late 30s (Harlow et al., 2012, Menopause). So the "starting in your 30s" claim isn't wrong, it's just describing the earlier end of a wide range, not the norm.
On symptoms: brain fog, sleep disruption, mood changes, and vasomotor symptoms like hot flashes are well-documented in perimenopause literature (Maki et al., 2010, Menopause). The link between thyroid function and these symptoms is also legitimate. Subclinical hypothyroidism can mimic perimenopause almost perfectly, and including it in a hormone panel is genuinely good clinical practice.
Vitamin D deficiency affecting mood and fatigue is supported, though its specific role in perimenopause symptom severity is more associative than causal (Lerchbaum and Obermayer-Pietsch, 2012, European Journal of Endocrinology).
What did they get wrong (or right)?
The good: the comprehensive panel approach, covering sex hormones, thyroid, and vitamin D, reflects real clinical thinking. Treating perimenopause symptoms in isolation without checking thyroid is genuinely a missed opportunity that happens in standard care.
The questionable: "bioidentical" is doing a lot of marketing work here. The term sounds reassuring and natural, but it is not a regulatory category recognized by the FDA. The North American Menopause Society has stated that the term is largely a marketing distinction, not a pharmacological one (NAMS Position Statement, 2012). Compounded bioidentical hormones are not equivalent in safety profile or consistency to FDA-approved hormone therapies, and this distinction matters for patients making decisions.
Also, framing all of these symptoms as being linkable back to hormones is a big swing. Brain fog and weight gain have numerous causes. Attributing them primarily to hormones without ruling out other factors first can lead patients toward hormone therapy when something else, like thyroid disease, nutrient deficiency, or sleep apnea, is the actual driver.
What should you actually know?
If you are in your late 30s or early 40s and experiencing these symptoms, getting a comprehensive hormone panel including thyroid and vitamin D is reasonable. That part of this video is solid advice. But a few things should give you pause before accepting the broader framing.
First, BHRT is not a magic reset. Symptom relief from hormone therapy is real and documented, but so are risks. Even low-dose estrogen therapy carries considerations around cardiovascular history and certain cancer risks, which require individual clinical evaluation, not a general wellness pitch on Instagram.
Second, the word "optimization" is used loosely in direct-to-consumer hormone content. Optimizing hormones toward what target, and according to whose reference range, is a conversation that requires a licensed clinician reviewing your specific labs and history. A video cannot do that.
Third, if you are specifically interested in testosterone therapy as a woman, the evidence base is narrower than for estrogen-based HRT. The Endocrine Society acknowledges testosterone's role in treating low sexual desire in postmenopausal women, but evidence for broader "optimization" use in perimenopausal women is still developing (Davis et al., 2019, Journal of Clinical Endocrinology and Metabolism).
The video is not dangerous. It is more promotional than educational, and the bioidentical framing needs scrutiny. But the core message, that hormonal changes can start before menopause and are worth evaluating comprehensively, holds up.